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Aim To assess the role of human platelet antigens (HPA), 
P-selectin gene (SELP) polymorphisms, and HPA and SELP 
haplotypes with factor V (FV) R506Q in ischemic pediat-
ric stroke (IPS) subtypes: cerebral sinovenous thrombosis 
(CSVT), perinatal (PAIS), and childhood (CAIS) arterial isch-
emic stroke.
Methods This case-control study enrolled 150 children 
with confirmed IPS and 150 age- and sex-matched con-
trols. FV R506Q and HPA-1 were genotyped with CVD Stri-
pAssay®, HPA-2 and HPA-3 with real-time polymerase chain 
reaction, SELP S290N, V599L, and T715P with high resolu-
tion melting analysis, and SELP N562D with sequence-spe-
cific polymerase chain reaction.
Results HPA-1b allele (odds ratio [OR] 2.75, 95% confidence 
interval [CI] 1.02-7.42, P = 0.048) and HPA-1a2a3b (OR 5.46, 
95% CI 1.51-19.76, P = 0.011), HPA-1b2a3a (OR 7.00, 95% 
CI 1.25-39.13, P = 0.028), and HPA-1b2b3a (OR 11.39, 95% 
CI 1.39-92.95, P = 0.024) haplotypes increased the risk for 
CSVT. HPA-3b allele was significantly associated with 2-fold 
lower risk for PAIS (OR 0.49, 95% CI 0.26-0.89, P = 0.020) and 
CAIS (OR 0.47, 95% CI 0.26-0.86, P = 0.014) and non-signifi-
cantly associated with increased risk for CSVT (OR 6.43, 95% 
CI 0.83-50.00, P = 0.022). HPA-1a2b3a haplotype was signif-
icantly associated with CAIS (OR 6.76, 95% CI 2.13-21.44, 
P = 0.001). The inclusion of FV R506Q in SELP haplotype 
analysis increased the risk for PAIS 4-fold in QNDVT carri-
ers (OR 8.14, 95% CI 0.93-71.33, P = 0.060) compared with 
NDVT haplotype (OR 2.45, 95% CI 0.98-6.18, P = 0.058), but 
the result was not significant.
Conclusion Individual HPAs, and particularly HPA haplo-
types, are involved in IPS subtypes pathogenesis. A possi-
ble risk-inducing synergistic effect of SELP haplotypes with 
FV R506Q is restricted to PAIS only.
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Ischemic pediatric stroke (IPS) is a relatively rare heteroge-
neous multifactorial disorder caused by arterial (ie, arterial 
ischemic stroke, AIS) or venous occlusion (ie, cerebral sino-
venous thrombosis, CSVT). According to the time of stroke 
onset, AIS is classified as perinatal (PAIS) and childhood AIS 
(CAIS) (1,2). IPS subtypes differ in incidence rates, etiology, 
presentation symptoms, and treatment strategies (2,3), and 
their predisposing disorders are still incompletely under-
stood and characterized (4-6). Risk factors for IPS include 
various inherited and acquired prothrombotic disorders 
(2,4,5). However, the role of different genetic risk factors in 
the etiology of IPS subtypes has been studied in a limited 
number of publications, and studies including multiple ge-
netic factors and haplotype analysis are extremely rare.
The most frequently investigated genetic risk factor is the 
polymorphism in factor V gene (FV) that causes amino 
acid change R506Q (FV Leiden, NM_000130.4:c.1601G>A, 
rs6025) and consequently activated protein C resistance 
and susceptibility to thrombosis (7). FV R506Q has been 
regularly associated with IPS, although in CSVT the asso-
ciation is weaker in children than in adults (4,8-10).
Platelets have a significant role in maintaining normal he-
mostasis. Changes in the structure of platelet membrane 
proteins can change platelet function and predisposition 
to thrombophilia. The effect of variations in platelet glyco-
protein receptor genes and the P-selectin adhesion mol-
ecule on their role in IPS has not been established yet (11).
Human platelet antigens (HPA) are genetically defined 
polymorphisms expressed on platelet membrane gly-
coproteins. In three out of six biallelic systems, ie, HPA-1 
(NM_000212.2:c.176T>C, rs5918) on glycoprotein IIIa, 
HPA-2 (NM_000173.5:c.482C>T, rs6065) on glycoprotein 
Ibα, and HPA-3 (NM_000419.3:c.2621T>G, rs5911) on gly-
coprotein IIb, a base-pair substitution leads to amino acid 
change in a platelet surface membrane glycoprotein. 
These biallelic systems modulate platelet receptor density, 
altering platelet function and thrombus formation (12-14). 
The role of HPAs in ischemic stroke has been recognized, 
but poorly investigated in adults (15-18) and particularly in 
children (9,19-21).
P-selectin mediates the interaction of activated endothelial 
cells or platelets with leukocytes (22,23). Multiple polymor-
phisms in P-selectin gene (SELP) have been described, but 
only five of them cause amino acid substitution that may 
influence its function: V168M (NM_003005.3:c.625G>A, 
rs6125), S290N (NM_003005.3:c.992G>A, rs6131), 
N562D (NM_003005.3:c.1807G>A, rs6127), V599L 
(NM_003005.3:c.1918G>T, rs6133), and T715P 
(NM_003005.3:c.2266A>C, rs6136) (24). SELP polymor-
phisms appear to be associated with several stages of 
thrombosis and associated diseases, including venous 
thromboembolism and atherothrombotic disease (25-27), 
cardiovascular disease, and myocardial infarction in adults 
(24,28-31). Although the relationship of different SELP poly-
morphisms to ischemic stroke in adults has been described 
(32-37), there are no reports regarding their role in IPS.
Since IPS subtypes have different pathophysiologic back-
grounds, it is justified to investigate the relative relation-
ship between thrombophilia polymorphisms and stroke 
subtypes. Therefore, the aim of this study was to assess the 
role of eight individual polymorphisms (FV R506Q, HPA-1, 
HPA-2, HPA-3, SELP S290N, N562D, V599L, and T715P) and 
their haplotypes (HPA-1/-2/-3, SELP S290N/N562D/V599L/
T715P, and FV R506Q /SELP S290N/N562D/V599L/T715P) in 
IPS subtypes: PAIS, CAIS, and CSVT.
PARtiCiPANts AND MetHoDs
Participants
This case-control study enrolled 150 children aged up to 
18 years with a confirmed diagnosis of PAIS, CAIS, or CSVT 
and 150 age- and sex-matched controls from the same 
geographical region with no history of thromboembolic 
or neurological events and with normal C reactive protein 
levels. Controls were recruited among children undergo-
ing minor surgery such as tonsillectomy and children with 
respiratory diseases at routine follow-up visits. All children 
were admitted to the University Hospital Centre Zagreb or 
Children’s Hospital Zagreb, Zagreb, Croatia, from 1999 to 
2018. The recruitment dynamics was five patients per year 
until 2004, with increasing tendency of seven to nine pa-
tients per year afterwards for AIS; one case of CSVT per year 
was recruited from 2008 to 2010 and three cases per year 
from 2013 to 2017.
The diagnosis was established after an extensive analysis 
of patients’ medical history and physical and neurologi-
cal examination; it was based on the presence of clinical 
symptoms and signs and confirmed by at least one brain 
imaging technique. Isolated computed tomography scans 
were used in selected cases only (N = 9) during the first 
recruitment years. Magnetic resonance imaging was per-
formed in 141 patients; in 72 to confirm computed to-
mography scan findings and in 69 patients, in the 
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later phase of research, as the only technique used. AIS was 
diagnosed based on the presence of neurological deficit of 
acute onset, seizures, or other signs of neonatal encephal-
opathy, and confirmed by neuroradiographic findings of 
parenchymal infarcts in cerebral arteries accordant with 
clinical manifestations. PAIS and CAIS were differentiated 
according to the definitions by Lynch (2).
CSVT was diagnosed after the neuroradiographic confir-
mation of a thrombus or flow interruption within cerebral 
veins or dural sinuses, together with clinical presentations 
of headache, seizure, lethargy, and focal or generalized 
neurologic deficit (38). Patients were included after a defi-
nite CSVT diagnosis by a neuroradiologist based on com-
puted tomography as the first imaging exam for excluding 
a tumor, subdural hematoma, or abscess followed by mag-
netic resonance imaging combined with magnetic reso-
nance angiography and venography as currently the best 
method for the confirmation of CSVT.
Written informed consent was obtained from all partici-
pants’ parents and additionally from all children older than 
12 years. The study was conducted in accordance with the 
tenets of the Declaration of Helsinki and approved by the 
Ethics Committee for Experimentation of the University of 
Zagreb Faculty of Pharmacy and Biochemistry (251-62-03-
14-95), Ethics Committee of the University Hospital Centre 
Zagreb (02/21/JG), and Ethics Committee of the Children’s 
Hospital Zagreb (01-26/18-14).
Molecular analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes and used for molecular analysis (Table 1). FV R506Q 
and HPA-1 were genotyped with CVD StripAssay® T and 
CVD StripAssay® A (ViennaLab Diagnostics, Vienna, Aus-
tria), respectively. Both tests were performed according to 
manufacturer’s instructions: each DNA sample was ampli-
fied in two parallel multiplex polymerase chain reactions 
(PCR) using biotin-labeled primers. Amplification products 
were selectively hybridized to a test strip containing allele-
specific oligonucleotide probes immobilized as an array 
of parallel lines. Bound PCR fragments were detected us-
ing streptavidin-alkaline phosphatase conjugate and color 
substrates. HPA-2 and HPA-3 were genotyped using previ-
ously described real-time PCR method based on TaqMan® 
technology on 7500 Real-Time PCR System (Applied Bio-
systems, Foster City, CA, USA) (39). Three positive controls 
representing different genotypes for each polymorphism 
were included in each run as a quality control step (40). 
Polymorphisms SELP S290N, V599L, and T715P were geno-
typed using PCR with specific primers followed by high res-
tABLe 1. Genotyping methods for eight individual polymorphisms*
Polymorphism Method Primer and minor groove binding probe sequences Reference
FV R506Q multiplex PCR using biotin labeled primers, 
hybridization to ASO probes
n.a.  –
HPA-1 multiplex PCR using biotin labeled primers, 
hybridization to ASO probes
n.a.  –
HPA-2 real-time PCR method based on TaqMan® 
technology
F: 5′-GAGCTCTACCTGAAAGGCAATGA-3′
R: 5′-TGTTGTTAGCCAGACTGAGCTTCT-3′
Pa: 5′-VIC-CTCCTGACGCCCACAC-NFQ-3′
Pb: 5′-FAM-CTCCTGATGCCCACAC-NFQ-3′
(39)
HPA-3 real-time PCR method based on TaqMan® 
technology
F: 5′-GCCTGACCACTCCTTTGCC-3′
R: 5′-TGCGATCCCGCTTGTGA-3′
Pa: 5′-VIC-CTGCCCATCCCCA-NFQ-3′
Pb: 5′-FAM-CTGCCCAGCCCCA-NFQ-3′
(39)
SELP S290N PCR with specific primers followed by high
resolution melting analysis
F: 5′-CCTTGGTTATTCTCTCCAGCTGTGC-3′
R: 5′-AGCCGGGCTGGCACTCAAAT-3′
(41)
SELP N562D PCR with sequence specific primers FN: 5′-CTCCACCTGYCATTTCTCTTGTA-3′
FD: 5′-CTCCACCTGYCATTTCTCTTGTG-3′
R: 5′-AAGTAGAACTGTCTTAGCAAGTAC-3′
(24)
SELP V599L PCR with specific primers followed by high
resolution melting analysis
F: 5′-TTGCAGGAGCCTCCCTTGTTATGAA-3′
R: 5′-GGTTCCCTGCCCAGGAGTGGT-3′
(41)
SELP T715P PCR with specific primers followed by high
resolution melting analysis
F: 5′-ATGAACTGCTCCAACCTCTG-3′
R: 5′-CCCACATGAAAATTGTACCTT-3′
(41)
*Aso – allele-specific oligonucleotide; n.a. – not applicable; FV – factor V gene; HPA – human platelet antigens; seLP- P – selectin gene; PCR – poly-
merase chain reaction; NFQ – nonfluorescent quencher.
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olution melting analysis on the LightCycler® 480 Real-Time 
PCR System (Roche Diagnostics, Mannheim, Germany) and 
results were analyzed using LightCycler® 480 Software (ver-
sion 1.5; Roche Diagnostics) (41). Control samples of each 
genotype previously confirmed by sequencing were used 
as positive controls (24). SELP N562D was genotyped us-
ing the previously described PCR with sequence specific 
primers on the Applied Biosystems GeneAmp 2720 Ther-
mal Cycler (24).
statistical analysis
Normality of distribution was tested with the Shapiro-
Wilk test (MedCalc software package version 9.3.2.0, Frank 
Schoonjans, the Netherlands). Continuous variables are ex-
pressed as medians and ranges. Descriptive analysis, Har-
dy-Weinberg equilibrium testing, and association analysis 
were performed with SNPStats (Catalan Institute of On-
cology, Barcelona, Spain) (42,43), a web-based tool for the 
analysis of association studies that analyzes single SNPs by 
multiple inheritance models and multiple SNPs (haplotype 
analysis) based on logistic regression. The obtained geno-
typing results of FV R506Q, SELP polymorphisms, and HPAs, 
SELP S290N/N562D/V599L/T715P, FV R506Q/SELP S290N/
N562D/V599L/T715P, and HPA-1/-2/-3 haplotypes are ex-
pressed as frequencies. Hardy-Weinberg equilibrium was 
tested for each individual polymorphism in patients and 
controls. The most common combined genotypes were 
used as reference haplotypes in the analysis of haplotype 
association with disease. Associations of each individual 
polymorphism and haplotype with the disease risk were 
expressed as odds ratios (OR) with corresponding 95% 
tABLe 2. Characteristics of patients with ischemic stroke and the control group*
Group
Number of 
participants
Male to 
female ratio
Age at diagnosis in years, 
median (range)
Age at testing in years, 
median (range)
IPS 150 1.54 1.9 (0.0-18.0) 4.6 (0.0-18.0)
AIS 132 1.59 1.9 (0.0-18.0) 5.9 (0.0-18.0)
PAIS  66 1.36 0.3 (0.0-12.0) 2.7 (0.0-18.0)
CAIS  66 1.87 6.8 (0.4-18.0) 7.9 (0.4-18.0)
CSVT  18 1.25 1.4 (0.0-12.8) 2.0 (0.0-15.4)
Control group 150 1.54 – 7.0 (0.0-18.0)
*Dash – not applicable; iPs – ischemic pediatric stroke; Ais – arterial ischemic stroke; PAis – perinatal arterial ischemic stroke; CAis – childhood arte-
rial ischemic stroke; CsVt – cerebral sinovenous thrombosis.
tABLe 3. individual polymorphisms in patients with ischemic pediatric stroke and its subtypes, and in the control group*
Polymorphism name
Patient  
group
 
Genotype
Genotype distribution 
in patient group, frequency
Genotype distribution 
in control group, frequency oR (95% Ci) P
FV R506Q PAIS GG 0.879 0.967 4.00 (1.26-12.74) 0.017
GA 0.121 0.033
HPA-1 CSVT aa 0.500 0.733 2.75 (1.02-7.42) 0.048
ab 0.500 0.247
bb 0.000 0.020
HPA-3 IPS aa 0.411 0.287 0.58 (0.36-0.93) 0.025
ab 0.411 0.507
bb 0.178 0.207
AIS aa 0.457 0.287 0.48 (0.29-0.78) 0.003
ab 0.388 0.507
bb 0.155 0.207
PAIS aa 0.453 0.287 0.49 (0.26-0.89) 0.020
ab 0.344 0.507
bb 0.203 0.207
CAIS aa 0.461 0.287 0.47 (0.26-0.86) 0.014
ab 0.431 0.507
bb 0.108 0.207
*oR – odds ratio; Ci – confidence intervals; iPs – ischemic pediatric stroke; FV – factor V gene; Ais – arterial ischemic stroke; PAis – perinatal arterial 
ischemic stroke; HPA – human platelet antigen; CsVt – cerebral sinovenous thrombosis; CAis – childhood arterial ischemic stroke.
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confidence intervals (CI) by using a dominant model (a ho-
mozygous or heterozygous variant in comparison with the 
homozygous wild-type). A P value of <0.050 was consid-
ered significant.
ResuLts
All IPS subtypes were more prevalent in boys (Table 2). 
Genotype distributions of all investigated individual poly-
morphisms, both in cases and controls, were in Hardy-
Weinberg equilibrium (results not shown), except HPA-3 
polymorphism in children with PAIS (P = 0.035).
Among the examined individual polymorphisms, IPS was 
associated with only three polymorphisms: FV R506Q, 
HPA-1, and HPA-3 (Table 3). PAIS was significantly asso-
ciated with FV R506Q; FV R506Q carriers had 4-fold in-
creased risk for PAIS. Carriers of at least one HPA-1b allele 
tABLe 4. Human platelet antigen HPA-1/-2/-3 haplotype frequencies in patients with ischemic pediatric stroke and its subtypes, and 
the control group
Group HPA-1/-2/-3 haplotype Haplotype frequency oR (95% Ci) P
IPS
HPA-1a2a3a
0.429 1.00 (Ref.) Ref.
AIS 0.446 1.00 (Ref.) Ref.
PAIS 0.485 1.00 (Ref.) Ref.
CAIS 0.429 1.00 (Ref.) Ref.
CSVT 0.138 1.00 (Ref.) Ref.
Control group 0.433 – –
IPS
HPA-1a2a3b
0.301 0.89 (0.59-1.34) 0.570
AIS 0.285 0.79 (0.51-1.21) 0.270
PAIS 0.323 0.86 (0.52-1.41) 0.540
CAIS 0.250 0.70 (0.39-1.24) 0.220
CSVT 0.542 5.46 (1.51-19.76) 0.011
Control group 0.351 – –
IPS
HPA-1b2a3a
0.078 1.45 (0.64-3.27) 0.370
AIS 0.079 1.32 (0.59-2.94) 0.500
PAIS 0.071 1.10 (0.43-2.79) 0.850
CAIS 0.086 1.54 (0.60-3.94) 0.370
CSVT 0.137 7.00 (1.25-39.13) 0.028
Control group 0.056 – –
IPS
HPA-1b2a3b
0.073 1.06 (0.52-2.18) 0.870
AIS 0.064 0.91 (0.43-1.92) 0.810
PAIS 0.052 0.74 (0.28-1.95) 0.550
CAIS 0.074 1.10 (0.44-2.75) 0.840
CSVT 0.044 3.17 (0.39-25.93) 0.280
Control group 0.060 – –
IPS
HPA-1a2b3a
0.094 3.97 (1.29-12.17) 0.016
AIS 0.104 4.46 (1.49-13.37) 0.008
PAIS 0.056 2.15 (0.58-8.02) 0.250
CAIS 0.147 6.76 (2.13-21.44) 0.001
CSVT 0.016 4.19 (0.11-154.50) 0.440
Control group 0.023 – –
IPS
HPA-1b2b3a
0.016 0.57 (0.11-2.99) 0.510
AIS 0.013 0.37 (0.05-2.58) 0.320
PAIS 0.014 0.45 (0.05-3.73) 0.460
CAIS 0.015 0.42 (0.04-3.99) 0.450
CSVT 0.068 11.39 (1.39-92.95) 0.024
Control group 0.027 – –
*Dash – not applicable; Ref. – reference haplotype; HPA – human platelet antigen; oR – odds ratio; Ci – confidence intervals; iPs – ischemic pediatric 
stroke; Ais – arterial ischemic stroke; PAis – perinatal arterial ischemic stroke; CAis – childhood arterial ischemic stroke; CsVt – cerebral sinovenous 
thrombosis.
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had a 2.75-fold increased risk for CSVT, while carriers of at 
least one HPA-3b allele had an approximately 2-fold lower 
risk for IPS and AIS, including both PAIS and CAIS. Carri-
ers of HPA-3b allele (OR 6.43, 95% CI 0.83-50.00, P = 0.022; 
data not shown) had an increased risk for CSVT, but the 
result was not significant. However, additive model re-
vealed a 2.23-fold increased risk for CSVT (95% CI 1.04- 
4.80, P = 0.034).
Carriers of HPA-1a2b3a had a 4-fold increased risk for IPS and 
AIS, and 7-fold for CAIS. Interestingly, three different HPA-1/-
2/-3 haplotypes showed a significant association with CSVT, 
resulting in five- to 11-fold increased risk: HPA-1a2a3b, HPA-1-
b2a3a, and HPA-1b2b3a. Haplotype HPA-1a2b3b was found 
in children with CSVT (0.054) and control group (0.050) 
only, but the result was not significant (OR 2.70, 95% CI 
0.32-22.46, P = 0.360; data not shown) (Table 4).
tABLe 5. SELP s290N/N562D/V599L/t715P and FV R506Q/SELP s290N/N562D/V599L/t715P haplotype frequencies in patients with ischemic 
pediatric stroke and its subtypes, and the control group*
Group
SELP s290N/N562D/ 
V599L/t715P haplotype
Haplotype 
frequency oR (95% Ci) P
FV R506Q/SELP s290N/ 
N562D/V599L/t715P haplotype
Haplotype 
frequency oR (95% Ci) P
IPS
SDVT
0.396 1.00 (Ref.) Ref.
RSDVT
0.405 1.00 (Ref.) Ref.
AIS 0.387 1.00 (Ref.) Ref. 0.397 1.00 (Ref.) Ref.
PAIS 0.413 1.00 (Ref.) Ref. 0.419 1.00 (Ref.) Ref.
CAIS 0.381 1.00 (Ref.) Ref. 0.386 1.00 (Ref.) Ref.
CSVT 0.445 1.00 (Ref.) Ref. 0.448 1.00 (Ref.) Ref.
Control group 0.405 – – 0.393 – –
IPS
SNVT
0.267 1.18 (0.74-1.87) 0.490
RSNVT
0.259 1.18 (0.73-1.89) 0.500
AIS 0.271 1.19 (0.74-1.93) 0.460 0.267 1.20 (0.74-1.95) 0.450
PAIS 0.266 1.18 (0.65-2.12) 0.590 0.259 1.19 (0.66-2.16) 0.570
CAIS 0.271 1.19 (0.66-2.14) 0.560 0.270 1.16 (0.64-2.09) 0.620
CSVT 0.249 0.96 (0.36-2.53) 0.930 0.219 0.82 (0.30-2.28) 0.700
Control group 0.240 – – 0.240 – –
IPS
NDVT
0.100 1.86 (0.83-4.17) 0.130
RNDVT
0.065 1.47 (0.61-3.52) 0.390
AIS 0.115 2.10 (0.93-4.75) 0.076 0.074 1.64 (0.67-4.01) 0.280
PAIS 0.108 2.45 (0.98-6.18) 0.058 0.061 1.89 (0.67-5.38) 0.230
CAIS 0.102 1.84 (0.68-5.00) 0.230 0.079 1.48 (0.51-4.30) 0.470
CSVT 0.041 0.48 (0.05-4.22) 0.510 0.040 0.47 (0.05-4.16) 0.500
Control group 0.070 – – 0.067 – –
IPS
NNVT
0.073 0.57 (0.28-1.17) 0.130
RNNVT
0.068 0.53 (0.25-1.13) 0.100
AIS 0.058 0.48 (0.22-1.05) 0.068 0.051 0.44 (0.19-1.00) 0.051
PAIS 0.063 0.48 (0.18-1.26) 0.140 0.049 0.40 (0.14-1.18) 0.098
CAIS 0.057 0.45 (0.15-1.36) 0.160 0.057 0.47 (0.16-1.39) 0.170
CSVT 0.154 1.45 (0.44-4.77) 0.540 0.155 1.44 (0.43-4.78) 0.550
Control group 0.108 – – 0.109 – –
IPS
SNVP
0.077 1.07 (0.57-2.01) 0.840
RSNVP
0.069 1.08 (0.58-2.04) 0.800
AIS 0.086 1.17 (0.61-2.24) 0.630 0.076 1.20 (0.63-2.29) 0.580
PAIS 0.032 0.70 (0.28-1.76) 0.450 0.028 0.76 (0.30-1.90) 0.550
CAIS 0.121 1.66 (0.80-3.48) 0.180 0.121 1.62 (0.77-3.40) 0.200
CSVT 0.008 0.37 (0.05-2.88) 0.340 0.007 0.37 (0.05-2.85) 0.340
Control group 0.077 – – 0.077 – –
IPS
SNLT
0.074 1.13 (0.52-2.44) 0.750
RSNLT
0.075 1.04 (0.48-2.21) 0.930
AIS 0.077 1.22 (0.56-2.68) 0.620 0.078 1.12 (0.52-2.45) 0.770
PAIS 0.087 1.44 (0.57-3.69) 0.440 0.088 1.32 (0.52-3.37) 0.560
CAIS 0.068 1.05 (0.40-2.74) 0.930 0.064 0.89 (0.33-2.42) 0.820
CSVT 0.056 0.81 (0.14-4.55) 0.810 0.056 0.79 (0.14-4.44) 0.790
Control group 0.066 – – 0.066 – –
*Dash – not applicable; Ref. – reference haplotype; FV – factor V gene; SELP – P-selectin gene; oR – odds ratio; Ci – confidence intervals; iPs – ischemic pediatric 
stroke; Ais – arterial ischemic stroke; PAis – perinatal arterial ischemic stroke; CAis – childhood arterial ischemic stroke; CsVt – cerebral sinovenous thrombosis.
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Six SELP S290N/N562D/V599L/T715P and of FV R506Q /SELP 
S290N/N562D/V599L/T715P haplotypes were identified in 
all study groups. Although haplotype NDVT was more fre-
quent in children with AIS and PAIS and least frequent in 
CAIS and AIS compared with control group, the result was 
not significant. Three rare haplotypes, NNLT, RNNLT, and 
QNDVT, were identified in AIS and controls only (results 
not shown). Haplotype QNDVT was more common in pa-
tients with PAIS than in control group (0.040 vs 0.002), but 
the result was not significant (OR 8.14, 95% CI 0.93-71.33, 
P = 0.060) (Table 5).
DisCussioN
This study demonstrated that various HPA genotypes and 
haplotypes were associated with IPS subtypes in a sample 
from Croatian child population and corroborated the hy-
pothesis that different IPS subtypes did not share the same 
genetic risk factors.
The present study revealed an almost 3-fold increased risk 
for pediatric CSVT in carriers of at least one HPA-1b allele. 
This makes it the first study to our knowledge that found a 
positive association of HPA-1 and pediatric CSVT. The only 
study that investigated HPA-1 in pediatric CSVT to date re-
ported more frequent HPA-1b allele-containing genotypes 
in CSVT than in both AIS and control group, but the results 
were not significant (20).
Consistent with previous findings on a moderate protec-
tive effect of HPA-3b allele for AIS and PAIS in Croatian pop-
ulation (9), the present study reported a 2-fold lower risk 
for IPS and CAIS, with the post-hoc calculated power of 0.51 
for PAIS, 0.54 for CAIS, 0.59 for IPS, and 0.82 for AIS with a 
significance level of 0.050. On the contrary to this, we iden-
tified an unexpectedly high harmful effect of HPA-3b allele 
in CSVT, as opposed to its protective effect in AIS, but these 
findings did not reach significance. Although the sample 
size for CSVT is small, the polymorphism frequency is high. 
Post-hoc power analysis revealed the power of 0.44, mean-
ing that additional 25 participants are needed to obtain 
the optimal power of 0.80.
HPA-1 and HPA-3 are both present on the most abundant 
glycoprotein IIb/IIIa complex, which, by binding fibrino-
gen, is essential for platelet aggregation and thrombus 
formation. Recently, Ichord has reported that major risk 
factors for CSVT are acute head and neck infections as 
well as acute systemic illness (44), a conclusion similar 
to that reached in our study. As acute illness is linked 
to higher fibrinogen level, enhanced platelet-fibrinogen 
interactions are possible, leading to the formation of clots 
that are more stable and resistant to lysis.
A further analysis of HPA-1/-2/-3 haplotypes demonstrated 
for the first time that particular haplotypes were positive-
ly associated with both AIS and CSVT. Haplotype HPA-1-
a2b3a conferred an almost 7-fold increased risk for CAIS, 
but not for PAIS or CSVT, with a consequent increased 
risk for AIS and IPS. Moreover, compared with the effect 
of HPA-1 alone, two HPA-1b allele containing haplotypes, 
HPA-1b2a3a and HPA-1b2b3a, conferred a three- to 4-fold 
increased risk for CSVT, respectively, whereas HPA-1a2a3b 
haplotype conferred a slightly lower risk.
Studies on HPAs in IPS are rare, provide contradictory re-
sults, and include only HPA-1 in differently defined pedi-
atric populations (19-21). Literature search revealed an as-
sociation of four specific HPA-1/-2/-3/-4 haplotypes with 
adult ischemic stroke and HPA-1b/2b/3a haplotype with 
coronary arterial disease, but the results are not compara-
ble to our study due to differences in studied populations 
and HPAs included in haplotype analysis (17,45).
Concordant with the majority of studies performed in 
adults (32-37), the present study found no association be-
tween individual SELP polymorphisms and any IPS subtype. 
The post-hoc power analysis revealed very low power for 
all individual SELP polymorphisms in IPS. Although no sig-
nificant association between SELP S290N/N562D/V599L/
T715P haplotypes and adult ischemic stroke was identified 
in Caucasian population (34), the present study revealed 
an increased presence of the NDVT haplotype in children 
with AIS and PAIS, but not in children with CAIS and CSVT, 
pointing to its possible role in the etiology of PAIS only. The 
effect of NDVT haplotype may be explained by a previous-
ly reported association of SELP S290N/N562D/T715P hap-
lotype NDT with increased soluble P-selectin plasma con-
centrations and the fact that SELP polymorphisms S290N 
and N562D are located within the SELP region important 
for the binding of P-selectins on leukocytes (26,46). As 
NNVT haplotype tends to decrease the risk for AIS, while 
NDVT haplotype tends to increase the risk for PAIS and AIS, 
it seems that N562D polymorphism is crucial for conferring 
the susceptibility to AIS.
The present study confirmed the association of FV R506Q 
with PAIS, which was previously established in a smaller 
study (8,46). Since the presence of multiple risk factors can 
have a synergistic effect (47), additional SELP haplotype 
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analysis also included FV R506Q, an established risk factor 
for IPS, which is located in the close proximity. Although 
the statistical significance was still not achieved, the inclu-
sion of FV R506Q increased the risk for PAIS 4-fold in QND-
VT carriers, as compared with NDVT haplotype alone, indi-
cating a possible synergistic effect of SELP haplotype and 
FV R506Q.
The strength of this study is the inclusion of all IPS sub-
types, including CSVT, enabling differentiation of their 
specific etiologies based on simultaneous identification 
of both harmful and protective genotype combinations. 
Moreover, the inclusion of haplotype analysis proved to 
be superior to the testing of single polymorphisms. To our 
knowledge, this is the only study to date investigating a 
possible association of SELP polymorphisms and HPA-1/-
2/-3, SELP S290N/N562D/V599L/T715P and FV R506Q/SELP 
S290N/N562D/V599L/T715P haplotypes with IPS.
The study limitations include the relatively small sample 
of children with IPS, as association studies usually require 
large cohorts to minimize possible statistical biases in con-
clusions and to strengthen the study power. Certainly, the 
results obtained for only 18 CSVT cases should be taken 
with caution, but nevertheless, they present the prelimi-
nary evidence of the enhanced risk-inducing effect of the 
HPA-1/-2/-3 haplotypes for CSVT. Considering the afore-
mentioned and the variable geographical and ethnical dis-
tribution of HPA genotypes (48), we cannot claim that the 
associations presented in this study can be applied to dif-
ferent populations or that the effect is limited to the Croa-
tian population only, warranting further research of plate-
let gene polymorphisms in IPS subtypes.
To evaluate genotype-phenotype associations, the present 
study used the candidate gene approach rather than ge-
nome-wide approach because of the lower cost and high-
er statistical power, especially if genes likely to play a role 
in the examined disease are formerly known, which is im-
portant for small-scale studies. Genome-wide association 
studies can reveal new genes or gene combinations even 
when their function was not previously known, but they 
usually require extensive funding and have low power due 
to the number of independent tests performed (49).
Our findings indicate that different IPS subtypes are char-
acterized by specific sets of inherited thrombophilia risk 
factors and that there is a variable role of polymorphisms 
in the etiology of IPS subtypes. In the era of personalized 
medicine, it is crucial to better understand the clinical value 
and physiological implications of different genetic entities 
if we want to treat patients properly and reduce morbidity 
and mortality. We believe that future trials with sample siz-
es increased through international collaborations and ex-
tensive haplotype analysis would achieve a greater power 
to confirm the role of all the examined haplotypes in the 
etiology of IPS subtypes.
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